Biogenera SpA

In which country will your order be delivered?

Please indicate the country where the purchase will be delivered. This will help us prepare your shipment.

Italy (€)

What is your language?

Tell us what your language is. It will make it easier to configure your custom product!

Order today, Sunday, and your custom wardrobe will be delivered already between 21.10.2024 and 25.10.2024

On-site measurement verification before production for all orders over 1000 CHF

FREE delivery for all orders

FREE assembly service for all orders over 1000CHF

Lacquering in the colour of your choice

Secure payment via Paypal

Switzerland (CHF) EN

The research done by BIOGENERA SpA has led to the identification and development of the first specific drug, the anti-tumoral anti-MYCN BGA002, for the cure of tumors of children with alterations of the tumoral gene MYCN (given a poor prognosis).
Within a few months BIOGENERA will start the phase 1 clinical studies, specifically in Neuroblastoma (currently the more lethal tumor in children). On demonstrating its high level of innovation, the medicine has already obtained status of Orphan Drug for the cure of Neuroblastoma from the European Medicines Agency (EMA) and from the Food and Drug Administration (FDA) in USA, and of the group of Soft Tissue Sarcomas (that include Rhabdomyosarcoma and Synovial Sarcoma) by EMA.

Click here to get more information...